Log in to save to my catalogue

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - t...

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - t...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3b762561ed1341cb9ed66582802669f3

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION

About this item

Full title

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Publisher

England: BioMed Central Ltd

Journal title

Current controlled trials in cardiovascular medicine, 2022-08, Vol.23 (1), p.688-12, Article 688

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

More than 2.7 million hospitalizations of COVID-19-infected patients have occurred in Europe alone since the outbreak of the coronavirus in 2020. Interventions against SARS-CoV-2 are still in high need to prevent admissions to ICUs worldwide. FX06, a naturally occurring peptide in humans and other mammals, has the potential to reduce capillary leak...

Alternative Titles

Full title

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients - the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_3b762561ed1341cb9ed66582802669f3

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3b762561ed1341cb9ed66582802669f3

Other Identifiers

ISSN

1745-6215

E-ISSN

1745-6215

DOI

10.1186/s13063-022-06609-x

How to access this item